CASI Pharmaceuticals – executive interview

CASI Pharmaceuticals – executive interview

CASI Pharmaceuticals — 1 video in collection

More on this equity

CASI Pharmaceuticals is focused on building a portfolio of drugs which it intends to produce for Chinese and worldwide markets. Its products are focused on the hematology and oncology space, including its first product, Evomela, launched in China in 2019. The company is also developing an anti-CD19 CAR-T therapy, CNCT19, and the anti-CD38 drug CID-103, among others. The goal is to seek approval through new pathways that have opened in the quickly changing Chinese regulatory environment.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free